PUBLISHER: DelveInsight | PRODUCT CODE: 1173643
PUBLISHER: DelveInsight | PRODUCT CODE: 1173643
DelveInsight's 'Acute Ocular Pain (AOP) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Acute Ocular Pain (AOP) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Canada, and South Korea.
The International Association for the Study of Pain (IASP) defines pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage," and pain is commonly stratified into two broad groups-nociceptive and neuropathic pain. Nociceptive pain refers to the direct activation of nociceptors due to actual or threatened damage to non-neural tissue and implies an intact somatosensory nervous system. This is typically associated with transient pain following injury, surgery, or infection in the eye. In contrast, neuropathic pain is caused by a lesion or disease of the intrinsic somatosensory nervous system, often in the absence of other tissue injuries.
Ocular pain is a myriad of symptoms ranging from acute sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from straightforward refractive errors to potentially sight-threatening disorders like glaucoma and uveitis. Most ophthalmologic conditions producing ocular pains are associated with symptoms and signs like red eye, photophobia, vision loss, or diplopia. Sometimes it poses a challenge to physicians when the pain is associated with a quiet or "white eye."
Diagnosis of AOP is based on previous medical and medication history and physical examination of the eye, which is then confirmed by tests like computed tomography (CT), magnetic resonance imaging (MRI), histopathologic examination for the detection of cancers, and culture of the eye to check for a bacterial infection.
Approaches to treating ocular pain come from neuroscience, neurology, and pain management rather than the field of ophthalmology. Clinicians should be alert and attuned to the possibility that a patient might have a pain syndrome rather than a report of physiologic nociception. Symptoms are the manifestation of signaling and should be the focus of treatment. Continued signaling converts peripheral-to-centralized pain and acute-to-chronic pain, so the goal of ocular pain management must be to reduce signaling, and various research focusing on new therapeutic entities may reduce the conversion of acute-to-chronic pain is underway.
The acute ocular pain (AOP) epidemiology division provides insights into the historical and current patient pool and the forecast trend of 6MM, Canada, and South Korea. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the number of cases of acute ocular pain (AOP) and their trends, along with assumptions undertaken.
The disease epidemiology covered in the report provides historical and forecasted acute ocular pain (AOP) epidemiology segmented as the number of cases of major eye disorders and the number of cases of acute ocular pain (AOP) in major eye disorders. The report includes the number of cases of acute ocular pain (AOP) scenario in the 6MM + Canada + South Korea from 2019 to 2032.
The epidemiology segment also provides the acute ocular pain (AOP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Canada, and South Korea.
The total number of cases of acute ocular pain (AOP) in the 6MM + Canada + South Korea countries was more than 9 million cases in 2021.
As per the estimates, the US had the highest acute ocular pain (AOP) patient population in 2021. Among the EU5 countries, Germany had the highest number of cases of acute ocular pain (AOP), with over 1 million cases, followed by France in 2021. On the other hand, Spain had the lowest number of cases of acute ocular pain (AOP), with apprixmately 540,000 cases in 2021.
We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, which will support the clients in potential novel treatments by identifying the overall scenario of the indications.
The Acute Ocular Pain (AOP) epidemiology report will allow the user to:
Study Period: 2019-2032.